Published in PLoS One on March 25, 2015
Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya. J Int AIDS Soc (2016) 0.84
The clock is ticking: the rate and timeliness of antiretroviral therapy initiation from the time of treatment eligibility in Kenya. J Int AIDS Soc (2015) 0.75
Predictors of dropout from care among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment clinic in sub-Saharan Africa. BMC Infect Dis (2016) 0.75
Willingness by people living with HIV/AIDS to utilize HIV services provided by Village Health team workers in Kalungu district, central Uganda. Afr Health Sci (2017) 0.75
Improving fold resistance prediction of HIV-1 against protease and reverse transcriptase inhibitors using artificial neural networks. BMC Bioinformatics (2017) 0.75
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health (2010) 6.48
Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg (2008) 6.39
Global health development assistance remained steady in 2013 but did not align with recipients' disease burden. Health Aff (Millwood) (2014) 2.26
The global financial crisis has led to a slowdown in growth of funding to improve health in many developing countries. Health Aff (Millwood) (2011) 2.21
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. PLoS One (2010) 2.05
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr (2008) 2.04
Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr (2008) 1.62
The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review. Health Policy Plan (2012) 1.47
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One (2013) 1.29
Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One (2012) 1.23
Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology (2009) 1.20
Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settings. Expert Opin Drug Saf (2008) 1.10
Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr (2011) 1.09
A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis (2011) 1.07
Adoption of new HIV treatment guidelines and drug substitutions within first-line as a measure of quality of care in rural Lesotho: health centers and hospitals compared. Trop Med Int Health (2012) 0.95
Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS One (2013) 0.93
Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials (2003) 0.90
Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection. Expert Opin Drug Saf (2012) 0.85
The potential to expand antiretroviral therapy by improving health facility efficiency: evidence from Kenya, Uganda, and Zambia. BMC Med (2016) 0.84
Patient satisfaction and perceived quality of care: evidence from a cross-sectional national exit survey of HIV and non-HIV service users in Zambia. BMJ Open (2015) 0.80
Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother (2015) 0.77
Determinants of Healthcare Utilisation and Out-of-Pocket Payments in the Context of Free Public Primary Healthcare in Zambia. Int J Health Policy Manag (2016) 0.75
Health Seeking Behaviour among Individuals with Presumptive Tuberculosis in Zambia. PLoS One (2016) 0.75
The adult prevalence of HIV in Zambia: results from a population based mobile testing survey conducted in 2013-2014. AIDS Res Ther (2016) 0.75
The effect of facility-based antiretroviral therapy programs on outpatient services in Kenya and Uganda. BMC Health Serv Res (2017) 0.75
The adult prevalence of HIV in Zambia: results from a population based mobile testing survey conducted in 2013-2014. AIDS Res Ther (2016) 0.75
The path to longer and healthier lives for all Africans by 2030: the Lancet Commission on the future of health in sub-Saharan Africa. Lancet (2017) 0.75